49 results about "Streptococcus pneumoniae pneumonia" patented technology

The present invention relates to cell-surface-located polypeptides of Streptococcus pneumoniae and their use in immunisation against Streptococcal infection, in diagnosis of Streptococcus and in identification of compounds with anti-Streptococcus activity. In a further aspect, the invention relates to antibodies capable of recognising cell surface-located polypeptides of Streptococcus pneumoniae and uses thereof.

The present invention relates to an immunogenic composition comprising(i) at least one Streptococcus pneumoniae protein;(ii) a Streptococcus pneumoniae capsular saccharide derived from a strain of a targeted serotype of Streptococcus pneumoniae; for use in enhancing antibody-mediated opsonic activity against the targeted serotype of Streptococcus pneumoniae.

The invention designs specific primers for streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex, and establishes a multiple landing PCR(Polymerase Chain Reaction) detection kit and a detection method for simultaneously detecting the bacteria, adopting agarose gel electrophoresis for detecting PCR products. The kit comprises a 10*PCR buffer solution, MgCl2, dNTP, TaqDNA polymerase, BSA(Bovine Serum Albumin), positive control DNAs of streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex, a streptococcus pneumoniae primer, a haemophilus influenzae type b primer and a mycobacterium tuberculosis complex primer. The kit can simultaneously quickly detect streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex in a lower respiratory tract sample. The multiple landing PCR detection kit and detection method established by the invention are quick, simple, specific and sensitive, and can be used for rapid diagnosis and epidemiological investigation of infection of streptococcus pneumoniae, haemophilus influenzae type b and mycobacterium tuberculosis complex.

The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.

The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and / or treatment of diseases caused by Streptococcus pneumoniae.

The invention provides the application of Streptococcus pneumoniae protein in resisting Streptococcus pneumoniae infection. The Streptococcus pneumoniae endopeptidase O (PepO) of the present invention is a subcutaneous immune adjuvant, mixed and fused with the 673rd to 863rd amino acid peptide of zinc metalloprotease B (ZmpB), and the prepared Streptococcus pneumoniae Protein vaccines have a good protective effect against Streptococcus pneumoniae infection.

The invention discloses a streptococcus pneumoniae autolysin small fragment gene expression protein as well as a preparation method and application thereof. The small fragment gene expression protein has the amino acid sequence shown in SEQIDNO:5. The preparation method comprises the steps of extracting the genome DNA of streptococcus pneumoniae (ATCC49619); by taking the obtained DNA as a template, carrying out PCR with a PCR primer having two restriction enzyme cutting sites BamHI and HindIII; splicing the PCR product recycled in glue cutting with a cloning vector to build a clone plasmid; and cutting glue to recycle 500bp small fragments through the clone plasmid built through double digestion respectively by BamHI and HindIII, connecting by a ligase and an expression vector, then converting into a competent cell, picking one and cloning, building a recombination expression plasmid, carrying out IPTG inducible expression, and recycling and purifying the protein. The streptococcus pneumoniae autolysin small fragment gene expression protein is used in preparation of antibacterial medicines.

The invention provides a gene segment of chemosynthetic streptococcus pneumoniae surface adhesin A as well as expression and application of the gene segment, and relates to the fields of a genetic engineering technology and diagnostic reagents. A bran-new gene sequence of an epitope is chemically synthesized by screening out a strong antigen epitope and total 197 amino acids from the 84th amino acid to the 280th amino acid in streptococcus pneumoniae adhesin A through computer analysis and selecting a codon which a procaryotic organism prefers. The genetic engineering technology is used for expressing the gene segment and preparing a strong antigen epitope segment of the streptococcus pneumoniae adhesin A. Expressed protein can be used for vaccine research and development, detection of streptococcus pneumoniae infection antibodies and preparation of monoclonal antibodies and polyclonal antibodies.

The invention relates to antibodies for resisting human streptococcus pneumoniae fam2 family PspA protein and an immunochromatographic kit applying the antibodies to detection on human streptococcus pneumoniae. The antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein are used for recognizing two linear antigenic epitopes composed of 34-47 amino acids and 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein respectively, and the sequence number of the human streptococcus pneumoniae fam2 family PspA protein in GenBank is WP_054380072.1; the sequences of the 34-47 amino acids and the 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein are SPQVVEKSSLEKKY and KLLDSLDPEGKTQD respectively. The two rabbit antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein have the advantages of being good in specificity, high in purity and titer and low in preparation cost.

The present invention provides a macrocyclic lactone and quinolone hybrid, characterized in that the macrocyclic lactone and quinolone hybrid include compounds with general formula I and general formula II, or, the macrocyclic lactone and quinolone hybrids include pharmaceutically acceptable salts formed by compounds of the general formula I and II and inorganic acids or organic acids, and the macrolide and quinolone hybrids can be better adapted to industrial production , and has good anti-susceptible and anti-drug resistance against common clinical erythromycin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Mora catarrhalis and Haemophilus influenzae Bacterial activity, can effectively treat clinical bacterial pneumonia or pneumonia caused by other microorganisms (such as mycoplasma, Legionella, etc.), and other tissue infections;

Severe influenza is associated with defects in pulmonary innate immunity, a phenomenon leading to secondary bacterial infections. The gut microbiota can control immune / inflammatory responses locally and at distant sites. The inventors hypothesized that perturbation of the gut microbiota during severe influenza might participate in bacterial superinfection post-influenza. Their data demonstrated that influenza infection profoundly altered the functionality of the gut microbiota as assessed by the altered production of short chain fatty acids (SCFAs). Remarkably, treatment of colonized (IAV microbiota) mice or IAV-infected mice with acetate, the main SCFA found systematically, reinforced host defenses against S. pneumoniae. The present invention thus relates to the use of short-chain fatty acids for the treatment of bacterial superinfections post-influenza.

The invention discloses the application of SPD_0310 protein as a target in the preparation of medicines for preventing and treating Streptococcus pneumoniae infection. In the present invention, it was found that the expression level of SPD_0310 in the triple mutant strain in which the three main iron transport genes of Streptococcus pneumoniae were knocked out at the same time was increased and could grow normally, indicating that the SPD_0310 protein may be involved in the interaction of various iron transport proteins. The present invention also found that the spd_0310 gene knockout strain has reduced infectivity to mice. Based on this, SPD_0310 can be used to prepare antibodies to the protein, so as to facilitate the development of antibody drugs. In addition, the present invention also found that the active center of the protein can bind heme, and proved that porphyrins can be used as substrates to compete with heme, indicating that porphyrins can be used as inhibitors of SPD_0310 to inhibit Streptococcus pneumoniae toxicity, which has broad application prospects in the field of antibacterial drugs.

The present invention discloses a method of treating or preventing a Streptococcus pneumoniae infection wherein the Streptococcus pneumoniae infection occurs in an environment where the free concentration of Zn2+ and / or Mn2+ is sufficiently low to upregulate the expression of at least one PhtX protein (for example PhtD) in the Streptococcus pneumoniae; comprising the step of administering a pharmaceutically effective amount of the PhtX protein to a human patient.